Mark Lunt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3540535/publications.pdf

Version: 2024-02-01

		8181]	13771
389	20,252	76		129
papers	citations	h-index		g-index
395	395	395		17798
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. Rheumatology, 2022, 61, 2524-2534.	1.9	9
2	Increased Frailty in Individuals With Osteoarthritis and Rheumatoid Arthritis and the Influence of Comorbidity: An Analysis of the UK Biobank Cohort. Arthritis Care and Research, 2022, 74, 1989-1996.	3.4	18
3	Sleep Disturbance and Quality of Life in Rheumatoid Arthritis: Prospective mHealth Study. Journal of Medical Internet Research, 2022, 24, e32825.	4.3	13
4	Heterogeneity in the association between weather and pain severity among patients with chronic pain: a Bayesian multilevel regression analysis. Pain Reports, 2022, 7, e963.	2.7	9
5	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research, 2022, 10, 1-240.	1.0	O
6	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology, 2022, 61, 4687-4701.	1.9	5
7	The impact of frailty on short-term mortality following primary total hip and knee arthroplasty due to osteoarthritis. Age and Ageing, 2022, 51, .	1.6	10
8	OA14aâ€fOutcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis. Rheumatology, 2022, 61, .	1.9	0
9	OA14bâ€fEtanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar?. Rheumatology, 2022, 61, .	1.9	O
10	1024 THE IMPACT OF FRAILTY ON 30-DAY MORTALITY FOLLOWING PRIMARY HIP AND KNEE ARTHROPLASTY DUE TO OSTEOARTHRITIS. Age and Ageing, 2022, 51 , .	1.6	0
11	1025 THE IMPACT OF DEPRIVATION AND FRAILTY ON THE LIKELIHOOD OF RECEIVING HIP AND KNEE ARTHROPLASTY DUE TO OSTEOARTHRITIS. Age and Ageing, 2022, 51, .	1.6	O
12	Risk of hospitalization and death due to infection in people with psoriasis: a populationâ€based cohort study using the Clinical Practice Research Datalink*. British Journal of Dermatology, 2021, 184, 78-86.	1.5	26
13	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. Rheumatology, 2021, 60, 2355-2365.	1.9	11
14	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. Rheumatology, 2021, 60, 4633-4642.	1,9	5
15	Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. American Journal of Epidemiology, 2021, 190, 1659-1670.	3.4	31
16	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e498-e501.	2.4	2
17	O27â€fFrailty and co-morbidity in people with osteoarthritis and rheumatoid arthritis. Rheumatology, 2021, 60, .	1.9	1
18	O32â€∫Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDS in rheumatoid arthritis patients: does line of therapy matter?. Rheumatology, 2021, 60, .	1.9	0

#	Article	IF	CITATIONS
19	OP0183â€IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIDISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES. Annals of the Rheumatic Diseases, 2021, 80, 110.2-111.	GH 0.9	0
20	OP0241â€SERIOUS INFECTION WITH TOCILIZUMAB COMPARED TO TNF-INHIBITORS AND OTHER BDMARDS IN RHEUMATOID ARTHRITIS PATIENTS: DOES LINE OF THERAPY MATTER?. Annals of the Rheumatic Diseases, 2021, 80, 148.2-148.	0.9	0
21	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e496-e498.	2.4	4
22	514 FRAILTY IN OSTEOARTHRITIS AND THE INFLUENCE OF CO-MORBIDITY. Age and Ageing, 2021, 50, ii5-ii7.	1.6	0
23	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research and Therapy, 2021, 23, 203.	3.5	3
24	Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study*. British Journal of Dermatology, 2021, 185, 952-960.	1.5	5
25	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. JAMA Dermatology, 2021, 157, 66.	4.1	14
26	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in Medicine, 2021, 40, 1718-1735.	1.6	50
27	Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study. Cardiovascular Endocrinology and Metabolism, 2021, 10, 37-44.	1.1	11
28	The effect of cemented acetabular component geometry on the risk of revision for instability or loosening. Bone and Joint Journal, 2021, 103-B, 1669-1677.	4.4	1
29	The effect of uncemented acetabular liner geometry and lip size on the risk of revision for instability or loosening. Bone and Joint Journal, 2021, 103-B, 1774-1782.	4.4	5
30	Effect of Timing and Duration of Statin Exposure on Risk of Hip or Knee Revision Arthroplasty: A Population-based Cohort Study. Journal of Rheumatology, 2020, 47, 441-448.	2.0	12
31	General practice (GP) level analysis shows that patients' own perceptions of support within primary care as reported in the GP patient survey (GPPS) are as important as medication and services in improving glycaemic control. Primary Care Diabetes, 2020, 14, 29-32.	1.8	0
32	Foot ulceration and its association with mortality in diabetes mellitus: a metaâ€analysis. Diabetic Medicine, 2020, 37, 211-218.	2.3	73
33	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 769-778.	2.4	27
34	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as †satisfactoryâ€. Rheumatology, 2020, 59, 1853-1861.	1.9	8
35	O18â€fNational variation and factors associated with long-term opioid use for non-cancer pain in the first year of use. Rheumatology, 2020, 59, .	1.9	O
36	$P212 \hat{a} \in f$ The effect of body weight in response to subcutaneous tocilizumab in patients with RA. Rheumatology, 2020, 59, .	1.9	0

#	Article	IF	CITATIONS
37	O27â€fEarly experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Rheumatology, 2020, 59, .	1.9	1
38	Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods. Diagnostic and Prognostic Research, 2020, 4, 9.	1.8	20
39	Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. PLoS Medicine, 2020, 17, e1003270.	8.4	81
40	Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation. BMJ Open, 2020, 10, e033231.	1.9	33
41	The treatment rate of erectile dysfunction (ED) in younger men with type 2 diabetes is up to four times higher than the equivalent nonâ€diabetes population. International Journal of Clinical Practice, 2020, 74, e13538.	1.7	1
42	COVIDâ€19: Generate and apply local modelled transmission and morbidity effects to provide an estimate of the variation in overall relative healthcare resource impact at general practice granularity. International Journal of Clinical Practice, 2020, 74, e13533.	1.7	6
43	A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Medical Research Methodology, 2020, 20, 132.	3.1	24
44	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 2020, 183, 294-302.	1.5	85
45	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology, 2020, 59, 2908-2919.	1.9	17
46	The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study. BMC Rheumatology, 2020, 4, 4.	1.6	6
47	Controlling antibiotic usageâ€"A national analysis of General Practitioner/Family Doctor practices links overall antibiotic levels to demography, geography, comorbidity factors with local discretionary prescribing choices. International Journal of Clinical Practice, 2020, 74, e13515.	1.7	1
48	SATO103â€THE EFFECT OF BODYWEIGHT ON RESPONSE TO INTRAVENOUS OR SUBCUTANEOUS TOCILIZUMAE PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 985.2-985.	3 <u>IN</u>	4
49	SAT0038â€CHANGES IN ILLNESS PERCEPTIONS IN PEOPLE WITH RHEUMATOID ARTHRITIS OVER THE FIRST YEAR OF TREATMENT WITH METHOTREXATE. Annals of the Rheumatic Diseases, 2020, 79, 949.2-950.	R _{0.9}	O
50	OP0087â€NATIONAL VARIATION AND FACTORS ASSOCIATED WITH THE TRANSITION FROM FIRST USE TO LONG-TERM OPIOID USE FOR NON-CANCER PAIN. Annals of the Rheumatic Diseases, 2020, 79, 58.1-58.	0.9	0
51	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (<scp>BADBIR</scp>). British Journal of Dermatology, 2019, 180, 329-337.	1.5	36
52	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2019, 59, 559-567.	1.9	1
53	How the weather affects the pain of citizen scientists using a smartphone app. Npj Digital Medicine, 2019, 2, 105.	10.9	49
54	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiology and Drug Safety, 2019, 28, 1290-1298.	1.9	19

#	Article	IF	Citations
55	Avoiding pitfalls when combining multiple imputation and propensity scores. Statistics in Medicine, 2019, 38, 5120-5132.	1.6	76
56	O17â€fChanging trends and prescribing patterns in opioid treated primary care patients with non-cancer pain over a 10-year period. Rheumatology, 2019, 58, .	1.9	0
57	O19â€fThe association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Rheumatology, 2019, 58, .	1.9	0
58	201â€fAnxiety, occupation and functional ability at the start of treatment and EULAR response are the main predictors of work outcomes in patients with rheumatoid arthritis commencing either methotrexate or biologics. Rheumatology, 2019, 58, .	1.9	0
59	The costs of drug prescriptions for diabetes in the NHS. Lancet, The, 2019, 393, 226-227.	13.7	9
60	Demographic factor clustering at a GP practice level in England and its relation to glycaemic outcomes: What we can learn from this. International Journal of Clinical Practice, 2019, 73, e13303.	1.7	0
61	Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS ONE, 2019, 14, e0215999.	2.5	13
62	O22â€fFrequency and reasons for switching back to etanercept originator following initial switch to etanercept biosimilar. Rheumatology, 2019, 58, .	1.9	2
63	Patient perception of support within primary care is as important as medication and services in achieving good glycaemic control. International Journal of Clinical Practice, 2019, 73, e13356.	1.7	0
64	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and realâ€world populations in psoriasis. British Journal of Dermatology, 2019, 181, 1265-1271.	1.5	15
65	Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes. BMJ Open, 2019, 9, e028278.	1.9	3
66	FRIO674â€THE ASSOCIATION BETWEEN JOINT EROSIONS PLUS AUTOANTIBODY POSITIVITY AT INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR RHEUMATOID ARTHRITIS AND DISEASE ACTIVITY AND DISABILITY OVER ONE YEAR., 2019,,.		0
67	SAT0141â€FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR. , 2019, , .		0
68	THU0668â€THE ASSOCIATION BETWEEN ANTI-CCP TITRE LEVEL AND DISEASEACTIVITY AND DISABILITY OVER C YEAR FOLLOWING THE INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR ANTI-CCP+ RHEUMATOID ARTHRITIS., 2019,,.	ONE	0
69	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.5	12
70	Developing a foot ulcer risk model: what is needed to do this in a realâ€world primary care setting?. Diabetic Medicine, 2019, 36, 1412-1416.	2.3	10
71	Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data. Pharmacoepidemiology and Drug Safety, 2019, 28, 179-186.	1.9	13
72	Reproductive Hormone Levels Predict Changes in Frailty Status in Community-Dwelling Older Men: European Male Ageing Study Prospective Data. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 701-709.	3.6	28

#	Article	IF	CITATIONS
73	Sodiumâ€glucose coâ€transporterâ€2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. Diabetes, Obesity and Metabolism, 2018, 20, 1659-1669.	4.4	7
74	Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2018, 48, 384-398.	3.4	12
75	Assumptions made when preparing drug exposure data for analysis have an impact on results: <scp>A</scp> n unreported step in pharmacoepidemiology studies. Pharmacoepidemiology and Drug Safety, 2018, 27, 781-788.	1.9	39
76	Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain. Scandinavian Journal of Pain, 2018, 18, 59-69.	1.3	18
77	Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis. BMJ Open, 2018, 8, e018752.	1.9	19
78	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
79	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 775-784.	0.7	71
80	Social deprivation modifies the association between incident foot ulceration and mortality in type 1 and type 2 diabetes: a longitudinal study of a primary-care cohort. Diabetologia, 2018, 61, 959-967.	6.3	34
81	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.9	50
82	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	1.9	53
83	Responsiveness of Single versus Composite Measures of Pain in Knee Osteoarthritis. Journal of Rheumatology, 2018, 45, 1308-1315.	2.0	11
84	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 2018, 154, 581.	4.1	74
85	Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 1089-1096.	1.9	22
86	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212426.	0.9	23
87	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: AÂProspective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 534-541.	0.7	62
88	The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study. Gynecologic Oncology, 2018, 148, 154-160.	1.4	36
89	Route to improving Type 1 diabetes mellitus glycaemic outcomes: realâ€world evidence taken from the National Diabetes Audit. Diabetic Medicine, 2018, 35, 63-71.	2.3	27
90	227â€fPredictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	0

#	Article	IF	Citations
91	ellâ \in fPatterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. Rheumatology, 2018, 57, .	1.9	O
92	OP0229â€The association of biologic drug-levels with infection risk: results from the british society for rheumatology biologics register for rheumatoid arthritis. , 2018, , .		3
93	$089\hat{a} \in f$ The association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. Rheumatology, 2018, 57, .	1.9	O
94	212â€f Multimorbidity is associated with increased disability but lower disease activity over time in patients with RA: results from the BSRBR-RA. Rheumatology, 2018, 57, .	1.9	0
95	e12â€fClinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. Rheumatology, 2018, 57, .	1.9	0
96	243â€fLongâ€ŧerm risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRâ€RA). Rheumatology, 2018, 57, .	1.9	0
97	Realâ€world practice level data analysis confirms link between variability within Blood Glucose Monitoring Strip (BGMS) and glycosylated haemoglobin (HbA1c) in Type 1 Diabetes. International Journal of Clinical Practice, 2018, 72, e13252.	1.7	7
98	$307 \hat{a} \in f$ Comparative risk of respiratory depression in patients treated with opioids for non-malignant pain. Rheumatology, 2018, 57, .	1.9	0
99	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1405-1412.	0.9	117
100	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, 1533-1540.	1.9	20
101	SAT0095â€A perceived biological cause of rheumatoid arthritisonset is associated with lower levels of depressed and anxious mood over one year compared to patients who attributed onset to other causes. , 2018, , .		0
102	OP0336â€The effect of timing and duration of statin exposure on the risk of revision following total hip or knee arthroplasty: a population-based cohort study. , 2018, , .		0
103	OP0031â€The importance of assessing multiplicative and additive interaction: examining the effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritisand concomitant type ii diabetes. , 2018, , .		0
104	OP0039â€High disease activity and disability at one year in two clusters of patients with rheumatoid arthritis defining themselves as in an acceptable state at treatment initiation. , 2018, , .		0
105	FRIO019â€Are disease activity, disability or psychological factors most associated with patients with rheumatoid arthritis being satisfied with their condition after 12 months following treatment onset?. , 2018, , .		0
106	OP0118â€Development of metabolic syndrome in patients with sle: results from an inception cohort. , 2018, , .		0
107	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 654-660.	0.9	122
108	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.9	88

#	Article	IF	Citations
109	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	3.8	29
110	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.9	107
111	Twentyâ€Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis and Rheumatology, 2017, 69, 1566-1575.	5.6	63
112	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 241-250.	2.2	40
113	Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years. Rheumatology, 2017, 56, 1510-1517.	1.9	10
114	Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2798-2806.	3.6	19
115	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology, 2017, 177, 1410-1421.	1.5	24
116	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases, 2017, 76, 1509-1514.	0.9	29
117	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Archives of Disease in Childhood, 2017, 102, 206.2-207.	1.9	14
118	001 Risk of serious infection associated with biologic therapies in psoriasis: AÂprospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2017, 137, S193.	0.7	0
119	FRIO105â€Fluctuating, unpredictable and challenging: how pain, fatigue and sleep disturbance impact quality of life in people with rheumatoid arthritis. , 2017, , .		1
120	A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes. Pharmacoepidemiology and Drug Safety, 2017, 26, 1474-1482.	1.9	5
121	Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Rheumatology, 2017, 56, 1189-1199.	1.9	11
122	Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well [®] study. British Journal of Dermatology, 2017, 176, 677-686.	1.5	39
123	159.â€∱THE IMPORTANCE OF ACHIEVING CLINICAL RESPONSE TO TREATMENT AND CHANGES IN PHYSICAL ABILI AND QUALITY OF LIFE ON WORKER PRODUCTIVITY OUTCOMES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56	TY 1.9	O
124	SAT0700â€Comparative risk of respiratory depression in patients treated with opioids for non-malignant pain. , 2017, , .		0
125	Response to:  Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al. Annals of the Rheumatic Diseases, 2017, 76, e4-e4.	0.9	2
126	OP0225â€The effect of a low versus high first prescribed dose of methotrexate on eular response at six months using data from the rams study. , 2017, , .		0

#	Article	IF	Citations
127	Reply. Arthritis and Rheumatology, 2017, 69, 2402-2403.	5.6	0
128	THU0112â€Stress and depression in patients with early inflammatory polyarthritis: natural history and associations with disease activity, disability and pain over five years. , 2017, , .		0
129	FRI0724â€Predictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. , 2017, , .		O
130	OP0123â€Prediction of progressive skin thickening in early diffuse systemic sclerosis using three-monthly skin scores from the european scleroderma observational study (ESOS). , 2017, , .		0
131	153. ASSESSMENT OF PREDICTORS OF AND OUTCOMES FOLLOWING ORTHOPAEDIC JOINT SURGERY OVER 2 YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS RECRUITED TO THE NORFOLK ARTHRITIS REGISTER. Rheumatology, 2017, 56, .	.0 1.9	1
132	THU0078â€Moderate Alcohol Consumption Is Not Associated with Serum Liver Abnormalities in Patients with Rheumatoid Arthritis Taking Methotrexate: Data from The Clinical Practice Research Database (CPRD):. Annals of the Rheumatic Diseases, 2016, 75, 207.2-207.	0.9	0
133	FRI0107â€No Increased Risk of High Grade Cervical Dysplasia in Women with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 467.1-467.	0.9	O
134	HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2618-2628.	5.6	23
135	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open, 2016, 2, e000273.	3.8	8
136	Patterns of Index Biologic Drug Registrations To A Pharmacovigilance Register of Psoriasis Patients. Value in Health, 2016, 19, A573.	0.3	0
137	Drug-specific risk, and associated factors, of vasculitis-like events in patients exposed to tumour necrosis factor alpha inhibitor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Lancet, The, 2016, 387, S55.	13.7	1
138	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2016, 55, 1601-1609.	1.9	28
139	Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology, 2016, 55, 840-847.	1.9	33
140	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology, 2016, 55, 2033-2039.	1.9	67
141	018 Impact of biologic therapies on the quality of life of psoriasis patients: results from the British Association of Dermatologists' Biologic Interventions Register. Journal of Investigative Dermatology, 2016, 136, S163.	0.7	0
142	Sensitivity to Change of Patientâ€Preference Measures for Pain in Patients With Knee Osteoarthritis: Data From Two Trials. Arthritis Care and Research, 2016, 68, 1224-1231.	3.4	23
143	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1337-1345.	5.6	16
144	Association Between Genetic Variation in <i>FOXO3</i> and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2629-2636.	5.6	32

#	Article	IF	CITATIONS
145	FRIO261â€Observational Study of Outcome in Patients with Early Diffuse Cutaneous Systemic Sclerosis Treated with Immunosuppressive Therapies (ESOS Study). Annals of the Rheumatic Diseases, 2016, 75, 528.2-529.	0.9	1
146	THU0294â€An International Consensus Exercise To Classify SLE Damage Items According To Their Likely Association with Steroids: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 293.1-293.	0.9	0
147	OP0043â€Corticosteroid Use over Time in The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort - A Descriptive Analysis: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 70.1-70.	0.9	0
148	Primary careâ€based screening for cardiovascular risk factors in patients with psoriasis. British Journal of Dermatology, 2016, 175, 348-356.	1.5	26
149	Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. European Journal of Epidemiology, 2016, 31, 1045-1055.	5.7	42
150	Composite symptom outcome measures in OA trials: do they have greater sensitivity to change than single outcomes?. Osteoarthritis and Cartilage, 2016, 24, S427-S428.	1.3	0
151	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2016, 75, 1139-1144.	0.9	41
152	Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis and Rheumatology, 2015, 67, 2487-2494.	5.6	45
153	SAT0355â€Risk and Characteristics of Drug Induced Vasculitis in Patients Exposed to Tumour Necrosis Factor α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 787.3-788.	0.9	0
154	THU0080â€Predictors and Consequences of Achieving Persistent Remission, Intermittent Remission or Never Achieving Remission in Patients with Recent Onset Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register (NOAR). Annals of the Rheumatic Diseases, 2015, 74, 221.1-221.	0.9	0
155	AB1162â€Prescriber Influence on Oral Glucocorticoid Prescribing in UK Primary Care for Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1291.2-1291.	0.9	0
156	FRIO358â€Risk and Characteristics of Drug Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 555.2-556.	0.9	0
157	FRI0145â€Choice and Effectiveness of Tocilizumab Among Patients with Rheumatoid Arthritis: An Observational Study from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 474.2-475.	0.9	0
158	PP3. Standardized mortality rates are increased in patients with severe JIA. Rheumatology, 2015, 54, ii6-ii6.	1.9	2
159	Demographics and disease characteristics of patients with psoriasis enrolled in the $\langle scp \rangle B \langle scp \rangle$ ritish $\langle scp \rangle A \langle scp \rangle$ ssociation of $\langle scp \rangle D \langle scp \rangle$ ermatologists $\langle scp \rangle B \langle scp \rangle$ iologic $\langle scp \rangle B \langle scp \rangle$ nterventions $\langle scp \rangle R \langle scp \rangle$ egister. British Journal of Dermatology, 2015, 173, 510-518.	1.5	87
160	PP2. Predicting treatment response to etanercept in JIA: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology, 2015, 54, ii5-ii6.	1.9	0
161	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.7	318
162	Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Research and Therapy, 2015, 17, 375.	3.5	25

#	Article	IF	CITATIONS
163	A randomised trial of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions. Annals of the Rheumatic Diseases, 2015, 74, 1164-1170.	0.9	112
164	Introduction to statistical modelling: linear regression: Fig. 1. Rheumatology, 2015, 54, 1137-1140.	1.9	22
165	Introduction to statistical modelling 2: categorical variables and interactions in linear regression. Rheumatology, 2015, 54, 1141-1144.	1.9	10
166	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	1.9	O
167	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. Journal of Investigative Dermatology, 2015, 135, 2189-2197.	0.7	132
168	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Annals of the Rheumatic Diseases, 2015, 74, 170-176.	0.9	55
169	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1087-1093.	0.9	162
170	Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology, 2015, 54, 1279-1285.	1.9	11
171	Vertebral Scheuermann's disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Osteoporosis International, 2015, 26, 2509-2519.	3.1	19
172	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
173	P2.â€fIncidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. Rheumatology, 2014, 53, i34-i35.	1.9	4
174	SP0187â€Imputation of Missing Data. Annals of the Rheumatic Diseases, 2014, 73, 49.4-49.	0.9	0
175	O23.â€∱The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. Rheumatology, 2014, 53, i38-i38.	1.9	0
176	39.â€fNon-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. Rheumatology, 2014, 53, i70-i70.	1.9	0
177	Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the BSPAR Etanercept Cohort Study. Rheumatology, 2014, , .	1.9	0
178	HLA-DRB1 associations with rheumatoid arthritis-related pulmonary fibrosis. Scandinavian Journal of Rheumatology, 2014, 43, 75-76.	1.1	6
179	Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time?. Journal of Rheumatology, 2014, 41, 1590-1599.	2.0	27
180	Selecting an Appropriate Caliper Can Be Essential for Achieving Good Balance With Propensity Score Matching. American Journal of Epidemiology, 2014, 179, 226-235.	3.4	223

#	Article	IF	CITATIONS
181	Mechanical pain threshold predicts response to intra-articular steroid therapy in symptomatic knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, S408-S409.	1.3	O
182	Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2014, 73, 1677-1682.	0.9	34
183	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq $1\ 1\ 0.78$	4314 rgB [*] 0.9	T /Overlock 1 75
184	Risk of birth defects associated with maternal pregestational diabetes. European Journal of Epidemiology, 2014, 29, 411-418.	5.7	44
185	Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register. Arthritis Care and Research, 2014, 66, 1296-1301.	3.4	113
186	The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Annals of the Rheumatic Diseases, 2014, 73, 252-255.	0.9	21
187	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Annals of the Rheumatic Diseases, 2014, 73, 684-690.	0.9	31
188	Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts. Seminars in Arthritis and Rheumatism, 2014, 44, 131-144.	3.4	59
189	Reducing Bias Amplification in the Presence of Unmeasured Confounding through Out-of-Sample Estimation Strategies for the Disease Risk Score. Journal of Causal Inference, 2014, 2, 131-146.	1.2	17
190	Model Misspecification When Excluding Instrumental Variables from PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. Epidemiologic Methods, 2014, 3, 83-96.	0.9	1
191	SAT0230â€The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis Who Have HAD A Prior Malignancy:. Annals of the Rheumatic Diseases, 2014, 73, 674.2-674.	0.9	3
192	FRIO557â€Standardised Mortality Rates Are Increased in Patients with Severe Juvenile Idiopathic Arthritis: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 588.1-588.	0.9	1
193	OP0029â€The Risk of Serious Infections in Patients Receiving Rituximab for Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 70.2-71.	0.9	1
194	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. Journal of Biopharmaceutical Statistics, 2013, 23, 461-476.	0.8	3
195	Enrichment of vitamin D response elements in RA-associated loci supports a role for vitamin D in the pathogenesis of RA. Genes and Immunity, 2013, 14, 325-329.	4.1	18
196	Lateral Wedge Insoles as a Conservative Treatment for Pain in Patients With Medial Knee Osteoarthritis. JAMA - Journal of the American Medical Association, 2013, 310, 722.	7.4	90
197	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2013, 65, 122-126.	3.4	19
198	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics Journal, 2013, 13, 137-147.	2.0	67

#	Article	IF	CITATIONS
199	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. Journal of Rheumatology, 2013, 40, 144-156.	2.0	22
200	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. Annals of the Rheumatic Diseases, 2013, 72, 1517-1523.	0.9	5
201	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
202	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2013, 72, 229-234.	0.9	146
203	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology, 2013, 52, 91-98.	1.9	116
204	Basic Science * 208. Stem Cell Factor Expression is Increased in the Skin of Patients with Systemic Sclerosis and Promotes Proliferation and Migration of Fibroblasts in vitro. Rheumatology, 2013, 52, i135-i172.	1.9	5
205	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. Annals of the Rheumatic Diseases, 2013, 72, 143-144.	0.9	30
206	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2013, 52, 1905-1913.	1.9	30
207	Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1983-1988.	0.9	126
208	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, 1429-1430.	0.9	3
209	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Annals of the Rheumatic Diseases, 2013, 72, 461-462.	0.9	33
210	OP0118â€Predictors of overall/cardiovascular mortality in patients with early inflammatory polyarthritis; the lipid-paradox?. Annals of the Rheumatic Diseases, 2013, 71, 93.1-93.	0.9	0
211	FRIO169â€Influence of anti-tnf therapy on the risk of myocardial infarction in subjects with rheumatoid arthritis: results from the bsrbr-ra. Annals of the Rheumatic Diseases, 2013, 72, A428.2-A428.	0.9	0
212	OP0088â€Changes in Baseline Severity of Inflammatory Polyarthritis Over Time. Annals of the Rheumatic Diseases, 2013, 72, A80.1-A80.	0.9	0
213	SP0175â€Methodological issues with observational data: Confounding by indication and missing data. Annals of the Rheumatic Diseases, 2013, 71, 43.1-43.	0.9	0
214	OP0117â€HDL-C and HBA1C predict the development of inflammatory polyarthritis: Results from the european prospective investigation of cancer (norfolk) and the norfolk arthritis register (EPIC-2-NOAR study). Annals of the Rheumatic Diseases, 2013, 71, 92.3-92.	0.9	0
215	OP0210â€Enrichment of vitamin D response elements in RA associated loci, suggests a role for vitamin D in the pathogenesis of RA. Annals of the Rheumatic Diseases, 2013, 71, 126.3-127.	0.9	0
216	OP0214â€Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study (ERAS) provides further replication of the TRAF1/C5 association with radiological damage. Annals of the Rheumatic Diseases, 2013, 71, 128.2-128.	0.9	0

#	Article	IF	CITATIONS
217	FRIO342â€Does exclusion of the ESR from JADAS affect validity in the clinical setting in assessment of new-onset juvenile inflammatory arthritis?:. Annals of the Rheumatic Diseases, 2013, 71, 429.3-430.	0.9	0
218	OP0126â€Early and sustained remission is associated with improved survival in patients with inflammatory polyarthritis: Results from the norfolk arthritis register. Annals of the Rheumatic Diseases, 2013, 71, 95.3-96.	0.9	1
219	FRIO067â€The relationship between fructose intake, alcohol consumption and serum URIC acid levels and the risk of inflammatory polyarthritis. Results from the european prospective investigation of cancer and the norfolk arthritis register: The EPIC-2-noar study:. Annals of the Rheumatic Diseases, 2013, 71, 332.1-332.	0.9	0
220	FRIO146â€The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy - results from the british society for rheumatology biologics register (BSRBR):. Annals of the Rheumatic Diseases, 2013, 71, 360.1-360.	0.9	0
221	OPO131â€Incidence of rheumatoid arthritis in the UK using the 2010 ACR/EULAR classification criteria for RA; and comparison with estimates using the 1987 ACR criteria:. Annals of the Rheumatic Diseases, 2013, 71, 97.3-98.	0.9	0
222	SATO148â€Does depression affect response to anti-tumour necrosis factor-α therapy in patients with rheumatoid arthritis (RA)? Results from the british society for rheumatology biologics register (BSRBR):. Annals of the Rheumatic Diseases, 2013, 71, 521.3-522.	0.9	0
223	AB0436â€Patient acceptable symptom state in rheumatoid arthritis patients starting methotrexate correlates with age and patient reported outcomes. Annals of the Rheumatic Diseases, 2013, 71, 662.9-662.	0.9	O
224	THU0222â€Oral Glucocorticoids and the Risk of Incident Type II Diabetes Mellitus in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study. Annals of the Rheumatic Diseases, 2013, 72, A239.3-A240.	0.9	3
225	SAT0113â€Common trajectories of HAQ disability progression over 15-years in the early rheumatoid arthritis study and the norfolk arthritis register. Annals of the Rheumatic Diseases, 2013, 71, 508.2-508.	0.9	2
226	THU0010â€A Weighted Genetic Risk Score Using 46 Loci to Predict Rheumatoid Arthritis Risk. Annals of the Rheumatic Diseases, 2013, 72, A167.3-A168.	0.9	3
227	THU0307â€Validation of JADAS in international league against rheumatism (ILAR) subtypes of juvenile idiopathic arthritis (JIA):. Annals of the Rheumatic Diseases, 2013, 71, 259.2-260.	0.9	O
228	THU0163â€Predictors of metabolic syndrome at enrolment into a multicentre international inception cohort of patients with SLE:. Annals of the Rheumatic Diseases, 2013, 71, 210.3-211.	0.9	0
229	OP0046â€A risk score to identify individuals at higher risk of inflammatory polyarthritis: Results from the european prospective investigation of cancer (norfolk) and the norfolk arthritis register (the) Tj ETQq1 1 0.784	4 3 0194 rgBT	/Dverlock
230	FRIOO64â€Obesity is associated with current and future disability in early inflammatory polyarthritis: Results from the norfolk arthritis register (NOAR):. Annals of the Rheumatic Diseases, 2013, 71, 330.3-331.	0.9	0
231	THU0007 Investigation of CRP Gene Polymorphisms as Predictors of Cardiovascular Mortality in Inflammatory Polyarthritis – Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2013, 72, A166.3-A167.	0.9	O
232	Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Annals of the Rheumatic Diseases, 2012, 71, 1984-1990.	0.9	93
233	Validation of JADAS in all ILAR subtypes of juvenile idiopathic arthritis (JIA) in the clinical setting. Archives of Disease in Childhood, 2012, 97, A124.2-A125.	1.9	4
234	Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. Journal of Rheumatology, 2012, 39, 240-246.	2.0	67

#	Article	IF	CITATIONS
235	Propensity Score Calibration in the Absence of Surrogacy. American Journal of Epidemiology, 2012, 175, 1294-1302.	3.4	23
236	Multiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2012, 71, 528-533.	0.9	11
237	Does exclusion of the ESR from JADAS affect validity in the clinical setting?. Archives of Disease in Childhood, 2012, 97, A125.1-A125.	1.9	O
238	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2012, 71, 869-874.	0.9	107
239	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Research and Therapy, 2012. 14. R214.	3.5	18
240	Bone marrow lesions in knee osteoarthritis change in 6–12 weeks. Osteoarthritis and Cartilage, 2012, 20, 1514-1518.	1.3	52
241	Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease. Arthritis Research and Therapy, 2012, 14, R239.	3.5	17
242	Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care and Research, 2012, 64, 1108-1115.	3.4	81
243	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology, 2011, 50, 124-131.	1.9	564
244	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1810-1814.	0.9	173
245	The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2011, 50, 78-84.	1.9	32
246	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Research and Therapy, 2011, 13, R159.	3.5	26
247	8 BONE MARROW LESIONS IN KNEE OSTEOARTHRITIS CHANGE IN 6 TO 12 WEEKS. Osteoarthritis and Cartilage, 2011, 19, S10.	1.3	2
248	Reduction of longâ€term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2011, 63, 945-952.	3.4	30
249	Influence of age and sex on functional outcome over time in a cohort of patients with recentâ€onset inflammatory polyarthritis: Results from the Norfolk arthritis register. Arthritis Care and Research, 2011, 63, 1745-1752.	3.4	22
250	The relationship between oral contraceptive use and functional outcome in women with recentâ€onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis and Rheumatism, 2011, 63, 2183-2191.	6.7	21
251	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 583-589.	0.9	188
252	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology, 2011, 50, 117-123.	1.9	77

#	Article	IF	CITATIONS
253	In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2011, 70, 1428-1432.	0.9	18
254	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with antiâ€TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1831-1834.	0.9	62
255	Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2011, 70, 642-645.	0.9	12
256	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2011, 50, 1341-1342.	1.9	43
257	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology, 2011, 50, 2311-2313.	1.9	42
258	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health and Quality of Life Outcomes, 2010, 8, 21.	2.4	28
259	Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. Arthritis Care and Research, 2010, 62, 755-763.	3.4	168
260	Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care and Research, 2010, 62, 664-675.	3.4	38
261	No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2010, 62, 3145-3153.	6.7	72
262	Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort. Arthritis and Rheumatism, 2010, 62, 3827-3829.	6.7	9
263	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, 49, 1197-1199.	1.9	49
264	Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 116-124.	2.0	51
265	Concurrent Oral 7 - Rheumatoid Arthritis: Clinical Aspects [OP48-OP53]: OP48. The Risk of Non-Melanoma Skin Cancer in Patients Receiving Anti-TNF Therapies for Rheumatoid Athritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, i21-i23.	1.9	0
266	Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2010, 69, 1086-1091.	0.9	185
267	Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology, 2010, 49, 1607-1608.	1.9	3
268	Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 563-570.	1.9	107
269	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010, 49, 2217-2219.	1.9	187
270	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases, 2010, 69, 522-528.	0.9	606

#	Article	IF	CITATIONS
271	Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2010, 69, 689-695.	0.9	41
272	Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1660-1664.	0.9	18
273	Control of weld composition when arc welding high strength aluminium alloys using multiple filler wires. Science and Technology of Welding and Joining, 2010, 15, 491-496.	3.1	15
274	The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2010, 69, 1834-1837.	0.9	20
275	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1570-1577.	1.9	73
276	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, $2010, \dots$	1.9	1
277	Control of weld composition when welding high strength aluminium alloy using the tandem process. Science and Technology of Welding and Joining, 2009, 14, 734-739.	3.1	15
278	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	3.4	71
279	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology, 2009, 48, 1323-1327.	1.9	50
280	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 69-74.	0.9	240
281	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology, 2009, 48, 1369-1374.	1.9	20
282	Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?. Annals of the Rheumatic Diseases, 2009, 68, 57-62.	0.9	77
283	Impact of prevalent and incident vertebral fractures on utility: results from a patient-based and a population-based sample. Quality of Life Research, 2008, 17, 159-167.	3.1	13
284	The risk of infection associated with tumor necrosis factor \hat{l}_{\pm} antagonists: Making sense of epidemiologic evidence. Arthritis and Rheumatism, 2008, 58, 919-928.	6.7	38
285	A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312. International Journal of Radiation Oncology Biology Physics, 2008, 72, S77.	0.8	8
286	Are reports of mechanical dysfunction in chronic oroâ€facial pain related to somatisation? A population based study. European Journal of Pain, 2008, 12, 501-507.	2.8	18
287	Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology, 2008, 47, 985-990.	1.9	35
288	Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology, 2008, 47, 991-995.	1.9	83

#	Article	IF	CITATIONS
289	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology, 2008, 47, 1000-1005.	1.9	67
290	Implementing Double-robust Estimators of Causal Effects. The Stata Journal, 2008, 8, 334-353.	2.2	79
291	Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology, 2007, 46, 1819-1823.	1.9	18
292	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 389-393.	0.9	36
293	The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology, 2007, 46, 533-538.	1.9	87
294	Lumbar disc degeneration: association between osteophytes, end-plate sclerosis and disc space narrowing. Annals of the Rheumatic Diseases, 2007, 66, 330-333.	0.9	71
295	Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 308-312.	0.9	127
296	Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology, 2007, 46, 983-988.	1.9	110
297	Acculturation and the prevalence of pain amongst South Asian minority ethnic groups in the UK. Rheumatology, 2007, 46, 1009-1014.	1.9	69
298	Determining aspects of ethnicity amongst persons of South Asian origin: The use of a surname-classification programme (Nam Pehchan). Public Health, 2007, 121, 231-236.	2.9	35
299	Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine, 2007, 25, 8500-8507.	3.8	98
300	Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis and Rheumatism, 2007, 56, 13-20.	6.7	379
301	Influence of inflammatory polyarthritis on cancer incidence and survival: Results from a community-based prospective study. Arthritis and Rheumatism, 2007, 56, 790-798.	6.7	38
302	Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis and Rheumatism, 2007, 56, 2422-2431.	6.7	160
303	Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis and Rheumatism, 2007, 56, 2896-2904.	6.7	292
304	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2007, 56, 2905-2912.	6.7	522
305	Development and validation of classification criteria for idiopathic orofacial pain for use in population-based studies. Journal of Orofacial Pain, 2007, 21, 203-15.	1.7	17
306	Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2006, 65, 617-622.	0.9	102

#	Article	IF	CITATIONS
307	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2006, 17, 1369-1381.	3.1	34
308	Rates of serious infection, including siteâ€specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2006, 54, 2368-2376.	6.7	694
309	Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2006, 66, 486-492.	0.9	60
310	Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2006, 65, 1449-1455.	0.9	15
311	The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors?. International Journal of Epidemiology, 2006, 35, 468-476.	1.9	295
312	Dietary \hat{l}^2 -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. American Journal of Clinical Nutrition, 2005, 82, 451-455.	4.7	97
313	Development and validation of the Manchester orofacial pain disability scale. Community Dentistry and Oral Epidemiology, 2005, 33, 141-149.	1.9	54
314	An evaluation of the decision tree format of the American College of Rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study. Arthritis and Rheumatism, 2005, 52, 2277-2283.	6.7	19
315	Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis and Rheumatism, 2005, 52, 2293-2299.	6.7	256
316	Prediction of ordinal outcomes when the association between predictors and outcome differs between outcome levels. Statistics in Medicine, 2005, 24, 1357-1369.	1.6	14
317	Dietary \hat{l}^2 -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. American Journal of Clinical Nutrition, 2005, 82, 451-455.	4.7	91
318	Long-term mortality amongst Gulf War Veterans: is there a relationship with experiences during deployment and subsequent morbidity?. International Journal of Epidemiology, 2005, 34, 1403-1408.	1.9	25
319	Low grip strength is associated with bone mineral density and vertebral fracture in women. Rheumatology, 2005, 44, 642-646.	1.9	100
320	Association between pain in the hip region and radiographic changes of osteoarthritis: results from a population-based study. British Journal of Rheumatology, 2005, 44, 337-341.	2.3	66
321	Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Annals of the Rheumatic Diseases, 2005, 64, 1595-1601.	0.9	204
322	Defining hip pain for population studies. Annals of the Rheumatic Diseases, 2005, 64, 95-98.	0.9	25
323	Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone, 2005, 36, 387-398.	2.9	88
324	Primary care consultation predictors in men and women: a cohort study. British Journal of General Practice, 2005, 55, 108-13.	1.4	34

#	Article	IF	Citations
325	Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. Journal of Public Health, 2004, 26, 277-284.	1.8	42
326	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology, 2004, 43, 731-736.	1.9	38
327	Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging—a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatology, 2004, 43, 986-991.	1.9	45
328	Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2004, 63, 280-284.	0.9	30
329	Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. Annals of the Rheumatic Diseases, 2004, 63, 843-847.	0.9	106
330	When Should the Doctor Order a Spine X-Ray? Identifying Vertebral Fractures for Osteoporosis Care: Results From the European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research, 2004, 19, 1982-1993.	2.8	82
331	Health-related quality of life and radiographic vertebral fracture. Osteoporosis International, 2004, 15, 113-119.	3.1	161
332	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporosis International, 2004, 15, 760-765.	3.1	106
333	A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2004, 50, 1604-1610.	6.7	124
334	Dietary risk factors for the development of inflammatory polyarthritis: Evidence for a role of high level of red meat consumption. Arthritis and Rheumatism, 2004, 50, 3804-3812.	6.7	147
335	Psychosocial and illness related predictors of consultation rates in primary care – a cohort study. Psychological Medicine, 2004, 34, 719-728.	4.5	51
336	Risk factors for Colles' fracture in men and women: results from the European Prospective Osteoporosis Study. Osteoporosis International, 2003, 14, 213-218.	3.1	74
337	Determinants of the Size of Incident Vertebral Deformities in European Men and Women in the Sixth to Ninth Decades of Age: The European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research, 2003, 18, 1664-1673.	2.8	33
338	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2003, 14, 19-26.	3.1	251
339	Changes in bone mineral density in the hip and spine before, during, and after the menopause in elite runners. Osteoporosis International, 2003, 14, 462-468.	3.1	7
340	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis and Rheumatism, 2003, 48, 46-53.	6.7	152
341	Functional and prognostic relevance of the â^'173 polymorphism of the macrophage migration inhibitory factor gene in systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173
342	Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone, 2003, 33, 505-513.	2.9	192

#	Article	IF	Citations
343	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 15-19.	0.9	40
344	Predictors of end stage lung disease in a cohort of patients with scleroderma. Annals of the Rheumatic Diseases, 2003, 62, 146-150.	0.9	107
345	Seventeen-point dermal ultrasound scoring system-a reliable measure of skin thickness in patients with systemic sclerosis. British Journal of Rheumatology, 2003, 42, 1559-1563.	2.3	135
346	Effects of psychosocial and individual psychological factors on the onset of musculoskeletal pain: common and site-specific effects. Annals of the Rheumatic Diseases, 2003, 62, 755-760.	0.9	113
347	Incidence of cancer among UK Gulf war veterans: cohort study. BMJ: British Medical Journal, 2003, 327, 1373-0.	2.3	40
348	Title is missing!. Spine, 2003, 28, 1195-1202.	2.0	39
349	Predictors of hip joint replacement in new attenders in primary care with hip pain. British Journal of General Practice, 2003, 53, 26-30.	1.4	42
350	Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densitometry. British Journal of Radiology, 2002, 75, 736-742.	2.2	46
351	The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. British Journal of Rheumatology, 2002, 41, 793-800.	2.3	513
352	Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary careâ€based inception cohort of patients. Rheumatology, 2002, 41, 246-252.	1.9	30
353	Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. Clinica Chimica Acta, 2002, 322, 121-132.	1.1	8
354	Falls explain between-center differences in the incidence of limb fracture across Europe. Bone, 2002, 31, 712-717.	2.9	47
355	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis and Rheumatism, 2002, 46, 906-912.	6.7	162
356	Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis and Rheumatism, 2002, 46, 2010-2019.	6.7	328
357	Mutation screening of the macrophage migration inhibitory factor gene: Positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 2402-2409.	6.7	242
358	Improving Risk Assessment: Hip Geometry, Bone Mineral Distribution and Bone Strength in Hip Fracture Cases and Controls. The EPOS Study. Osteoporosis International, 2002, 13, 48-54.	3.1	122
359	Detection of Osteoporosis by Dual Energy X-ray Absorptiometry (DXA) of the Calcaneus: Is the WHO Criterion applicable?. Calcified Tissue International, 2002, 70, 475-482.	3.1	34
360	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2002, 13, 565-571.	3.1	191

#	Article	IF	CITATIONS
361	Defining Incident Vertebral Deformities in Population Studies: A Comparison of Morphometric Criteria. Osteoporosis International, 2002, 13, 809-815.	3.1	42
362	Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research, 2002, 17, 716-724.	2.8	551
363	A Statistical Method to Minimize Magnification Errors in Serial Vertebral Radiographs. Osteoporosis International, 2001, 12, 909-913.	3.1	12
364	The Effects of Lifestyle, Dietary Dairy Intake and Diabetes on Bone Density and Vertebral Deformity Prevalence: The EVOS Study. Osteoporosis International, 2001, 12, 688-698.	3.1	135
365	Incidence of Distal Forearm Fracture in British Men and Women. Osteoporosis International, 2001, 12, 555-558.	3.1	259
366	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2001, 12, 85-90.	3.1	159
367	Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis and Rheumatism, 2001, 44, 1033-1042.	6.7	77
368	Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. Arthritis and Rheumatism, 2001, 44, 1248-1253.	6.7	68
369	Vertebral Morphometry: Repeat Scan Precision Using the Lunar Expert-XL and the Hologic 4500A. A Study for the "WISDOM" RCT of Hormone Replacement Therapy. Osteoporosis International, 2000, 11, 537-543.	3.1	25
370	Determinants of bone density and prevalence of osteopenia among female runners in their second to seventh decades of age. Bone, 2000, 26, 591-598.	2.9	35
371	Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. Bone, 2000, 27, 151-159.	2.9	94
372	Measurement imprecision in vertebral morphometry of spinal radiographs obtained in the European Prospective Osteoporosis Study: consequences for the identification of prevalent and incident deformities British Journal of Radiology, 1999, 72, 957-966.	2.2	20
373	Structure of the Femoral Neck in Hip Fracture: Cortical Bone Loss in the Inferoanterior to Superoposterior Axis. Journal of Bone and Mineral Research, 1999, 14, 111-119.	2.8	184
374	Assessing the Rate of Bone Loss: A Technique Revisited. Journal of Bone and Mineral Research, 1999, 14, 1990-1990.	2.8	1
375	Bone Mineralization and Turnover in Preterm Infants at 8-12 Years of Age: The Effect of Early Diet. Journal of Bone and Mineral Research, 1999, 14, 810-820.	2.8	130
376	Bone Density Reduction in Various Measurement Sites in Men and Women with Osteoporotic Fractures of Spine and Hip: The European Quantitation of Osteoporosis Study. Calcified Tissue International, 1999, 64, 191-199.	3.1	89
377	Does the presence of postmenopausal symptoms influence susceptibility to vertebral deformity?. Maturitas, 1999, 32, 179-187.	2.4	16
378	Determinants of the first decade of bone loss after menopause at spine, hip and radius. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 261-273.	0.5	27

#	Article	IF	CITATIONS
379	Effects of Menstrual History and Use of Medications on Bone Mineral Density: The EVOS Study. Calcified Tissue International, 1998, 63, 271-276.	3.1	20
380	Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study. Journal of Bone and Mineral Research, 1997, 12, 1883-1894.	2.8	177
381	Cortical Remodeling Following Suppression of Endogenous Estrogen with Analogs of Gonadotrophin Releasing Hormone. Journal of Bone and Mineral Research, 1997, 12, 1231-1240.	2.8	22
382	Population-based geographic variations in dxa bone density in Europe: The evos study. Osteoporosis International, 1997, 7, 175-189.	3.1	148
383	Letter. Osteoporosis International, 1996, 6, 183-184.	3.1	2
384	Radial Cortical and Trabecular Bone Densities of Men and Women Standardized with the European Forearm Phantom. Calcified Tissue International, 1996, 58, 135-143.	3.1	4
385	Radial cortical and trabecular bone densities of men and women standardized with the European forearm phantom. Calcified Tissue International, 1996, 58, 135-143.	3.1	34
386	Dual X-ray absorptiometryâ€"cross-calibration and normative reference ranges for the spine: Results of a European Community Concerted Action. Bone, 1995, 17, 247-254.	2.9	65
387	Dual X-ray absorptiometry of the proximal femur: Normal european values standardized with the european spine phantom. Journal of Bone and Mineral Research, 1995, 10, 315-325.	2.8	60
388	Growth in children and adolescents with juvenile idiopathic arthritis after 2 years of treatment with etanercept: results from the BSPAR Etanercept Cohort Study. Rheumatology, 0, , .	1.9	0
389	072. $\hat{a} \in f$ The Association Between Oral Glucocorticoid Therapy and Mortality in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. Rheumatology, 0, , .	1.9	0